BTIG analyst Mark Massaro raised the firm’s price target on Guardant Health (GH) to $100 from $80 and keeps a Buy rating on the shares. The company delivered another robust 12% top line beat and raised its guide well in excess of the beat, the analyst tells investors in a research note. The stock’s sharp move higher is well-deserved and a testament to the strong execution and rediscovered credibility in Guardant’s strong leadership team, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $100 from $75 at Mizuho
- Guardant Health price target raised to $85 from $70 at Barclays
- Guardant Health price target raised to $100 from $75 at Canaccord
- Guardant Health Reports Strong Q3 2025 Growth
- Guardant Health: Strong Performance and Growth Potential Drive Buy Rating